IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

Clinical Data Highlight PlaCCine’s Six-Month Durability, Temperature Stability, and Manufacturing Advantages Over mRNA Vaccines

IMUNON Seeks Strategic Partner for PlaCCine^® to Advance Novel Technology and Fund Core Pipeline with Non-Dilutive Capital

Read more at globenewswire.com